 |
Analyst Meet / AGM
01-Aug-11
|
|
|
|
|
|
|
|
AGM
|
|
|
|
Orchid Chemicals and Pharmaceuticals
|
|
The company plans to commercialize more than 100 products in the next four years
|
|
|
|
|
|
Orchid Chemicals and Pharmaceuticals held its 19th Annual General Meeting on 29 July 2011. The meeting was chaired and addressed by Chairman and Managing Director of the company K Raghavendra Rao.
Hey highlights of the meet:
- The year 2010-11 was an important year for the company, as it was the first year after it has transferred its generic injectable formulations business to Hospira. Interestingly, It has surpassed the guidance given at the beginning of the financial year by a considerable margin.
- This superior performance for the year ended March 2011, was the result of the following multiple growth factors,
- Increased supplies to Hospira
- Contractual agreements with other global pharmaceuticals players in regulated markets
- Returns from the company's front end acquisitions in US
- Further, The year 2010-11, marks an inflection point in the company's history as it implemented a critical strategic shift in the business model- from a supply-push to a demand-pull approach, taking into account product requirements, supply constraints of large multinational players and aligned the supply strategies accordingly.
- The alignment with large generic companies helped the company predict its growth, demand and revenue potentials effectively. The company put in place an operating canvas that incorporated long-term supply arrangements involving niche products, which assured sustainable growth with strong margins. This shift to a more robust business model helped the company bring down key working capital parameters like inventory and receivable days.
- It is focused on creating a business model that aims to capitalize an existing infrastructure while diversifying into new niche therapeutic segments, enabling to sustain long-term business and profitability growth over the coming years.
- With the acquisition of Karalex Pharma LLC in 2010-11, it has completed its coverage of the entire generic pharmaceutical business cycle- from manufacturing capability to product delivery. This positions the company favorably in the lucrative and growing US generic market and internalizes shareholder value. To further strengthen the formulations business in the regulated markets, the company entered into an agreement with Alvogen, for marketing eight high-potential oral products in the US.
- The company strengthened its product basket by developing a product range, which would yield and deliver strong revenues going forward covering the antibiotic and nonantibiotic domains.
- Out of the cumulative filling at 67 across US and Europe for the year ended March 2011, company received approvals for 38. In addition, company is focusing on commercializing more than 100 products in the next four years.
- The company endorsed a second agreement with Hospira for supplying the API for their patented Add-Vantage vials a specialized vial technology. It also entered in to an alliance with a global innovator to supply a patented cephalosporin formulation, which will add to robust revenues. Additionally, the company is evaluating other opportunities that create-win propositions for both partners. These initiatives should accelerate the company's growth over the long-term.
- The Company excited about the prospects for 2011-12. It is by estimated that the company will grow by a strong double-digit percentage, harvesting the benefits sowed during earlier years. The initiative it has taken in the past year was only partially reflected in the numbers of FY'11, expected to deliver a full year impact in 2011-12. Further, The following growth drivers it expect to make impact for 2011-12 are:
- Benefits from existing API supply contracts
- Additional new supply arrangements in the API and formulation segments
- Increased presence in the CRAMS segment
- New product launches in the regulated markets
- Further penetration in the domestic and emerging markets
- Its Cephalosporin API manufacturing facility located in Alathur (Chennai), was recently issued a Closure Notice by the Tamilnadu Pollution Control Board (TNPCB) citing some non-compliance with regard to the disposal of solid waste.
- Further, it is in discussions with the TNPCB at the highest levels to provide them the evidence and the assurance they seek to ascertain the environment-friendly nature of the operations at this site, and are confident that this matter should be resolved soon.
|
|
|
|
Previous News |
Sensex up 273 pts; IT shares outperforms
(
Market Commentary
-
Mid-Session
06-Jun-24
14:42
)
|
|
|
Orchid Pharma gains on DCGI nod for new antibiotic drug combination
(
Hot Pursuit
-
06-Jun-24
12:38
)
|
|
|
Orchid Pharma reports consolidated net loss of Rs 15.01 crore in the June 2022 quarter
(
Results
-
Announcements
11-Aug-22
08:49
)
|
|
|
Orchid Pharma Ltd leads gainers in 'B' group
(
Hot Pursuit
-
09-Feb-24
12:15
)
|
|
|
Orchid Pharma reports consolidated net loss of Rs 44.72 crore in the December 2020 quarter
(
Results
-
Announcements
10-Feb-21
08:08
)
|
|
|
Orchid Pharma to announce Quarterly Result
(
Corporate News
-
30-Oct-23
19:26
)
|
|
|
Orchid Pharma receives EIR report for API facility in Alathur, Tamil Nadu
(
Corporate News
-
21-Sep-17
13:33
)
|
|
|
Orchid Pharma receives DCGI approval for Enmetazobactam
(
Corporate News
-
06-Jun-24
13:06
)
|
|
|
Orchid Pharma to take up quarterly results
(
Corporate News
-
24-Feb-18
10:57
)
|
|
|
Orchid Chemicals & Pharmaceuticals reports standalone net loss of Rs 47.56 crore in the June 2015 quarter
(
Results
-
Announcements
15-Aug-15
11:10
)
|
|
|
Orchid Chemicals recovers after 4-day 5% slide
(
Hot Pursuit
-
26-Nov-12
15:23
)
|
|
|
|
|
|
Other Stories |
|
|
|
|
|
|
|
|
|
|
|
|
|